Mixed mode chromatography resins market is valued at USD 172 million in 2025 and is projected to grow at a CAGR of 15.7%, reaching USD 743 million by 2035. These resins use multimodal ligands, enabling protein binding through ionic, hydrogen bonding, and hydrophobic interactions, offering improved selectivity, resolution, and capacity compared to single-mode systems. This growth is driven by the increasing demand for sophisticated purification methods in biologics and biosimilar manufacturing, with a focus on process efficiency, scalability, and regulatory compliance in pharmaceutical and biopharmaceutical companies.
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7451
The surge in monoclonal antibody and gene therapy production further fuels adoption, as mixed mode resins provide high binding capacity and flexibility for complex separations.
Market Segmentation and Trends:
The mixed mode chromatography resins market is segmented by type, application, and region, providing a detailed understanding of its dynamics. Types include ion exchange-hydrophobic type, hydroxyapatite type, and others. The ion exchange-hydrophobic type is expected to be the most profitable segment, with a CAGR of 17.1% from 2025 to 2035, due to its high binding capacity, flexibility, and selectivity, essential for biologics and biosimilars production, particularly in monoclonal antibody and gene therapy applications.
Applications encompass antibodies production, vaccine production, non-antibody proteins, antibody-drug conjugate, and separation of low molecular weight impurities. Antibodies production is set to be the most profitable application, with a CAGR of 18.4% from 2025 to 2035, driven by the growth of monoclonal antibody drugs and biosimilars, demanding high accuracy and scalability in purification, especially for managing high titers and eliminating host cell proteins.
Regionally, North America leads due to strong R&D, while Asia Pacific, particularly China at a 16.5% CAGR, is emerging rapidly with policy initiatives like "Healthy China 2030." Trends include advancements in high-performance resins and increased investment in biomanufacturing.
Driving Factors Behind Market Growth:
The mixed mode chromatography resins market is propelled by several key drivers. The growing demand for biologics and biosimilars, particularly monoclonal antibodies, requires advanced purification techniques to achieve high purity and yield. Increased R&D investments in cell and gene therapies boost the need for resins with superior selectivity and capacity. Regulatory compliance and quality standards in biopharmaceuticals push for efficient, scalable processes, where mixed mode resins excel in removing impurities like host cell proteins.
The expansion of contract development and manufacturing organizations (CDMOs) supports market growth by providing specialized purification services. Environmental and sustainability concerns favor resins that reduce solvent use and waste. Additionally, the rise in vaccine production, accelerated by global health challenges, demands robust separation technologies. These factors, combined with technological innovations in ligand design, position the market for sustained expansion, addressing the complexities of modern bioprocessing.
Browse Full Report: https://www.factmr.com/report/mixed-mode-chromatography-resin-market
Recent Developments and Key Players:
The mixed mode chromatography resins market is moderately concentrated, with recent developments highlighting innovation and capacity expansions. In 2024, Merck KGaA expanded its chromatography resin manufacturing capacity to meet demand for resins used in monoclonal antibodies and other biologic products. In 2024, Bio-Rad Laboratories launched a new series of high-performance ion-exchange chromatography resins for the biopharmaceutical sector, offering improved capacity and selectivity for protein purification.
Key players include Thermo Fisher Scientific (25-30% market share), Cytiva (Danaher) (20-25%), Merck KGaA (MilliporeSigma) (15-20%), Agilent Technologies (10-15%), Bio-Rad Laboratories (8-12%), Tosoh Corporation (5-10%), GE Healthcare (now part of Cytiva in chromatography), Purolite Corporation, Avantor, JSR Micro Inc., Kaneka Corporation, Sepragen Corporation, Repligen Corporation, Bio-Works Technologies, Mitsubishi Chemical Corporation, Hitachi Chemical (now part of Showa Denko), Sartorius AG, and Waters Corporation. Competitor analysis reveals a focus on R&D for next-generation resins with increased selectivity and binding capacity.
Thermo Fisher and Cytiva lead through comprehensive portfolios and global reach, while Merck emphasizes bioprocessing solutions. Strategic acquisitions and collaborations enhance offerings, targeting high-value biologics and biosimilars to capture market share in a competitive landscape.
Regional Insights and Opportunities:
North America dominates the mixed mode chromatography resins market, driven by a robust R&D environment and biologics manufacturers, with the United States focusing on cell and gene therapy and biosimilars. Europe follows, with Germany at a 15.8% CAGR supported by precision biomanufacturing and EMA norms. The Asia Pacific region is the fastest-growing, led by China at 16.5% CAGR, fueled by public and private R&D investments and initiatives like "Healthy China 2030," emphasizing biosimilars and monoclonal antibodies. India grows at 16.2% CAGR, benefiting from cost-effective manufacturing and "Make in India" policies.
South Korea at 16.4% CAGR is driven by investments from Samsung Biologics and Celltrion. The United Kingdom (15.3% CAGR), France (15.6%), Italy (15.4%), and Australia-New Zealand (15.2%) offer opportunities through biotech startups and personalized medicine. Latin America and the Middle East & Africa present potential via expanding biomanufacturing. Emerging markets offer growth through strategic investments in R&D and collaborations for technology transfer.
Challenges and Future Outlook:
The mixed mode chromatography resins market faces challenges, including high development costs for advanced ligands and scalability issues in bioprocessing. Regulatory compliance and quality assurance pose hurdles, particularly for biosimilars. However, the market's future is optimistic, with opportunities in next-generation resin technologies and expanding biomanufacturing in emerging economies.
As demand for monoclonal antibodies and gene therapies rises, innovations in ion-exchange and hydroxyapatite types will drive growth. The market is well-positioned to more than quadruple by 2035, revolutionizing biologics purification through efficient, selective solutions.
Comments
0 comment